The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 15, 2022

Filed:

Mar. 17, 2022
Applicant:

Qx Therapeutics Inc., Branford, CT (US);

Inventors:

Dianqing Wu, New Haven, CT (US);

Ho Yin Lo, Bethel, CT (US);

Assignees:

Qx Therapeutics Inc., Branford, CT (US);

Yale University, New Haven, CT (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/506 (2006.01); A61K 31/496 (2006.01); A61P 11/00 (2006.01); A61P 31/14 (2006.01); A61K 31/675 (2006.01);
U.S. Cl.
CPC ...
A61K 31/506 (2013.01); A61K 31/496 (2013.01); A61K 31/675 (2013.01); A61P 11/00 (2018.01); A61P 31/14 (2018.01);
Abstract

The present invention provides methods and compositions for treating and preventing lung injuries due to or associated with coronavirus infections that cause Severe Acute Respiratory Syndrome, including COVID-19. More specifically the present invention provides methods for treating or preventing the lung injuries associated with SARS-CoV-2 infections, such as acute lung injury (ALI), lung fibrosis, and acute respiratory distress syndrome (ARDS). The methods comprise administering a therapeutically effective amount of a pharmaceutical composition comprising a protein kinase inhibitor compound having MAP3K2/MAP3K3 inhibition activity, such as pazopanib or nintedanib, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, to a patient in need thereof. The present invention also provides devices for administering the compositions.


Find Patent Forward Citations

Loading…